Skip to main content

Advertisement

SpringerLink
Log in

The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC).

Procedures

This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels.

Results

Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients.

Conclusion

FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CEA:

Carcinoembryonic antigen

CT:

Computed tomographic, computed tomography

FDG:

2-deoxy-2-[18F]fluoro-d-glucose

FNAB:

Fine-needle aspiration biopsy

FSE:

Fast spin-echo

MIP:

Maximum intensity projection

MRI:

Magnetic resonance imaging

MTC:

Medullary thyroid carcinoma

PET:

Positron emission tomography

SD:

Standard deviation

SUVmax :

Maximum standard uptake value

References

  1. You YN, Lakhani V, Wells SA, Moley JF (2006) Medullary thyroid cancer. Surg Oncol Clin N Am 15:639-660

    Article  PubMed  Google Scholar 

  2. Kebebew E, Ituarte PHG, Siperstein AE, Duh Q-Y, Clark OH (2000) Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging system. Cancer 88:1139-1147

    Article  CAS  PubMed  Google Scholar 

  3. de Groot JWB, Kema IP, Breukelman H, van der Veer E, Wiggers T, Plukker JTM, Wolffenbuttel BHR, Links TP (2006) Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid 16:1163-1170

    Article  PubMed  Google Scholar 

  4. Schlumberger M, Pacini F (2003) Medullary thyroid carcinoma. In: Schlumberger M, Pacini F, eds. Thyroid tumors. Paris: Nucleon, 305-335

    Google Scholar 

  5. Hyer SL, Vini L, A´Hern R, Harmer C (2000) Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 26:686-690

    Article  CAS  PubMed  Google Scholar 

  6. Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma. Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142

    Article  PubMed  Google Scholar 

  7. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648

    Article  CAS  PubMed  Google Scholar 

  8. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling time in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084

    Article  CAS  PubMed  Google Scholar 

  9. Behr TM, Becker W (2005) Imaging of medullary thyroid cancer. In: Biersack HJ, Grünwald F (eds) Thyroid cancer, 2nd edn. Springer Verlag, Berlin, chapter 18:311-333 (ISBN-10 3-540-22309-6)

    Google Scholar 

  10. Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli J, Schlumberger M (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative imaging. Br J Cancer 88:1537-1542

    Article  CAS  PubMed  Google Scholar 

  11. Machens A, Schneyer U, Holzhausen H, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029-2034

    Article  CAS  PubMed  Google Scholar 

  12. Rohren EM, Turkington TG, Coleman RE (2004) Clinical Application of PET in Oncology. Radiology 231:305-332

    Article  PubMed  Google Scholar 

  13. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507

    Article  CAS  PubMed  Google Scholar 

  14. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE (2008) Impact of positron emission tomography / computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26:2155-22161

    Article  PubMed  Google Scholar 

  15. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE (2009) Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry. J Nucl Med 49:1928-1935

    Article  Google Scholar 

  16. Gillies RJ, Robey I, Gatenby RA (2008) Causes and Consequences of Increased Glucose Metabolism of Cancers. J Nucl Med 49 (Suppl 2):24S-42S

    Article  CAS  PubMed  Google Scholar 

  17. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FGD-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786-794

    Article  PubMed  Google Scholar 

  18. Szakáll S, Ésik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Ágoston P, Trón L (2002) 18F-FDG PET Detection of Lymph Node Metastases in Medullary Thyroid Carcinoma. J Nucl Med 43:66-71

    PubMed  Google Scholar 

  19. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Körber C, Grünwald F (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study. Eur J Nucl Med 28:1671-1676

    Article  CAS  PubMed  Google Scholar 

  20. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Tovo NN, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli J-P, Baudin E, Schlumberger M (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metabol 92:4185-4190

    Article  CAS  Google Scholar 

  21. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F (2007) Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metabol 92:4590-4597

    Article  CAS  PubMed  Google Scholar 

  22. Yen TWF, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB (2003) Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134:890-900

    Article  PubMed  Google Scholar 

  23. Ong SC, Schröder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, Shaha AR, Tuttle RM, Shah JP, Larson SM (2007) Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels. J Nucl Med 48:501-507

    Article  CAS  PubMed  Google Scholar 

  24. Koopmans KP, de Groot JWB, Plukker JTM, de Vries EGE, Kema IP, Sluiter WJ, Jager PL, Links TP (2008) 18F-Dihydroxyphenylalanine PET in Patients with Bochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation. J Nucl Med 49:524-531

    Article  CAS  PubMed  Google Scholar 

  25. Giraudet AL, Ghulzan AA, Aupérin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239-246

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Department of Radiology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    Trond Velde Bogsrud

  2. Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    Dimitrios Karantanis, Mark A. Nathan, Brian P. Mullan, Gregory A. Wiseman & Val J. Lowe

  3. Department of Otorhinolaryngology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    Jan L. Kasperbauer

  4. Division of Ultrasonography, Department of radiology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    Carl C. Reading

  5. Department of Clinical Biochemistry, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    Trine Björo

  6. Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    Ian D. Hay

Authors
  1. Trond Velde Bogsrud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitrios Karantanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark A. Nathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian P. Mullan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gregory A. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan L. Kasperbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carl C. Reading
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Trine Björo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ian D. Hay
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Val J. Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Val J. Lowe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bogsrud, T.V., Karantanis, D., Nathan, M.A. et al. The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma. Mol Imaging Biol 12, 547–553 (2010). https://doi.org/10.1007/s11307-009-0276-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-009-0276-2

Key words

Search

Navigation